Stocks finished off the month with a whimper, but Oppenheimer technical analyst Ari Wald says the sell-off is a great buying opportunity.» Read More
In the world of nearly 400 publicly-traded biotechs, analyst coverage is especially important. Many of the firms are micro caps and when an analyst initiates coverage it can help put a baby biotech on investor and reporter radar screens.
That's what worked in 1990, in an environment much like this one.
When combing through Barron's over the weekend I always make it a point to check out the "Short Interest" tables when they appear. I'm curious, in particular, about the ups and downs in Dendreon. Right now it's 39th on Barron's list of the Top-40 largest short positions.
GM's shares have plummeted to less than $12, the lowest level since 1955. That means the world's largest auto maker has a stock market value of only about $7 billion.
Stocks closed lower Monday, snapping last week's rally, amid a fresh wave of financial worries and inflation concerns. General Motors rose.
D-mab is a twice-a-year shot and Fosamax is a once-a-week pill. Doctors say compliance--patients taking their meds--is a challenge with the most common osteoporosis drugs in part because you have to take them with a tall glass of water and then stay upright for at least half an hour.
An experimental osteoporosis drug that is considered to be crucial to the future of biotechnology giant Amgen strengthened bones more than today's most widely-used treatment, research showed.
My recent post on the new Evista commercial from Eli Lilly elicited a few opinions including one from a woman who says she participated in a focus group for the spot. Laura Bliss says her comments at the time were that the "togas...made the women look like they were already sick....
Stocks finished near session lows as oil prices soared and a measure of wholesale inflation surged, sparking worries that the Federal Reserve will start focusing on rising prices rather than slowing growth.
Stocks tumbled Tuesday as oil prices blew past $129 a barrel and a measure of wholesale inflation surged, sparking worries that the Federal Reserve will start focusing on rising prices rather than slowing growth.
If sales of Amgen's anemia drugs hadn't fallen so much last year, the American biotechnology industry probably would have turned its first profit in history. That's one of the main conclusions of Ernst & Young's comprehensive annual report on the sector that came out today.
Up until last month, AMGN had been atop the list of pharmaceutical manufacturer donors and PFE was in a close second. But the CRP says they flip-flopped in the most recent month that figures are available. So far, in the 2008 election cycle, Pfizer's given $862,000 to candidates and Amgen has forked over $852,000.
Occasionally -- when the bosses will let me -- I take a day to network, learn and maybe pick up a story idea by attending a biotech or healthcare investment conference. Many firms put on the events for their clients and they often invite reporters to hang out. ... The PR guy told me a couple of sessions during the day would be "closed" to me. It wasn't clear what the closed sessions were all about, and so my curiousity was piqued...
Amgen is in major belt-tightening mode. Still it held its annual shareholder shindig at the swanky Four Seasons Hotel in Westlake Village, CA. The 400-500 investors who showed up were treated to valet parking, soft drinks, and a nice spread of cheeses, vegetable crudite, fruit and sweets
There's no money left under the pillow, but Amgen execs and directors have been handed a gift. One of the most outspoken, large, individual investors in the biotech company who's been calling for the Board and CEO to go won't be attending its annual shareholder meeting after all.
After the closing bell yesterday, Merck announced that it plans to get rid of 12-hundred or around 15 percent of its sales reps. Like Schering-Plough, the company is having to adjust to lower sales of its Vytorin and Zetia cholesterol drugs and on top of that the Food and Drug...
The morning after Amgen reported its first quarter earnings my inbox runneth over with analyst research reports on the biotech behemoth. The company beat the Street by eight cents a share. But the focus remains on the anemia drug franchise.
Amgen Inc., the world's largest biotechnology company, reported earnings of $1.12 per share on first-quarter revenues of $3.6 billion on Thursday, beating most Wall Street expectations on cost-cutting measures.
The irreverent producers of "Squawk on the Street" who are stationed in the pod next to mine here at CNBC like to call it "Pharmapalooza." They're referring to weeks like the one coming up when nearly every big drug company reports earnings.
Dow component and healthcare conglomerate (drugs, consumer products, medical devices) Johnson & Johnson beat and boosted. That's Wall Street jargon for earnings coming in higher than expectations and the guidance for the rest of the year being raised. So, why did the stock go down?